ABVC BioPharma, Inc. (ABVC) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing new drugs and medical devices derived from plants, primarily in the fields of CNS, Oncology/Hematology, and Ophthalmology. The company operates through wholly-owned subsidiaries (BriVision, BioLite Holding, BioKey) and a majority-owned subsidiary (AiBtl BioPharma). The financial statements for the prior year periods have been restated to correct accounting errors related to share-based payments, convertible debt interest, and non-controlling interests.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2024 (Restated) |
|---|---|---|---|
| Revenue | $795,950 | $795,950 | $507,623 |
| Net Loss | $(1,287,523) | $(4,564,546) | $(4,462,510) |
| Net Loss Attributable to ABVC | $(1,246,513) | $(4,345,610) | $(4,171,304) |
| Operating Expenses | $1,964,360 | $4,952,348 | $4,507,538 |
| Stock-Based Compensation | $1,136,217 | $2,756,603 | $2,410,381 |
| Cash and Cash Equivalents | $192,068 (as of Sept 30, 2025) | ||
| Restricted Cash | |||
| Total Current Assets | $4,072,569 | ||
| Total Current Liabilities | $6,507,520 | ||
| Working Capital Deficit | $(2,434,951) | ||
| Convertible Notes Payable (Third Parties) | $68,791 (Net) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 104% quarter-over-quarter and 57% year-over-year (nine-month comparison), driven primarily by milestone payments recognized from licensing agreements with related parties OncoX BioPharma and ForSeeCon Eye Corporation.
- Expense Increase: Operating expenses rose significantly, particularly stock-based compensation, which increased by $346,222 for the nine-month period compared to the prior year. This was due to employee compensation and non-employee share-based payments for consultants.
- Asset Acquisition: Total assets increased from $7.54 million (Dec 31, 2024) to $21.18 million (Sept 30, 2025). This surge is largely due to the recognition of land acquisitions in Taiwan (Puli Township and Taoyuan City) valued at approximately $11.55 million combined, recorded via equity issuance.
- Debt Reduction: The company successfully converted and repaid significant portions of its "Lind Notes" convertible debt. Outstanding convertible notes payable to third parties decreased from $950,046 (Dec 31, 2024) to $68,791 (Sept 30, 2025).
- Restatements: Prior period financials (2024) were restated to correct misapplications of accounting standards regarding stock compensation, convertible debt interest, and non-controlling interests.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has a working capital deficit of $2.43 million and reported a net loss of $4.56 million for the nine months ended Sept 30, 2025. Management states these conditions raise substantial doubt about the company's ability to continue as a going concern. The company plans to address this through private/public offerings, cost containment, and collecting licensing fees.
- NASDAQ Compliance: The company received a deficiency notice regarding minimum stockholders' equity requirements in April 2025 but subsequently received a notification in May 2025 that it had regained compliance based on Q1 2025 equity levels. However, the company remains under scrutiny for minimum bid price requirements.
- Clinical Developments:
- Vitargus: Phase II study paused due to Serious Adverse Events (SAEs) in Thailand; company is investigating root causes.
- ABV-1505 (ADHD): Clinical Study Report submitted to the FDA in March 2025; company evaluating next steps.
- ABV-1519 (Lung Cancer): Phase I/II study expected to begin in Q4 2025.
- Related Party Transactions: A significant portion of revenue and asset acquisitions involve related parties (e.g., Shuling Jiang, OncoX, ForSeeCon). Land acquisitions were funded largely through the issuance of restricted stock and warrants rather than cash.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses previously identified, which led to the restatement of financials.
Key Facts for Investor Verification
- Liquidity Risk: Verify the company's ability to raise additional capital given the substantial doubt regarding its going concern status and the reliance on related party funding.
- Revenue Quality: Assess the sustainability of revenue, which is currently driven by milestone payments from related parties (OncoX, ForSeeCon) rather than commercial product sales.
- Asset Valuation: Scrutinize the valuation and title transfer status of the newly acquired land assets in Taiwan, which significantly inflated the balance sheet but may face regulatory hurdles regarding foreign ownership.
- Debt Obligations: Confirm the status of remaining cash obligations associated with the converted Lind Notes and the potential for future dilution from outstanding warrants.
- Restatement Impact: Review the full details of the 2023 and 2024 restatements to understand the historical accuracy of the company's financial reporting.